This page is updated frequently with new Allergy-related patent applications.
|| List of recent Allergy-related patents
| Phl p 5a derivatives having reduced allergeneity and retained t-cell reactivity|
The present invention relates to the preparation and use of variants of the group 5 allergen of the pooideae which are characterised by reduced ige reactivity compared with the known wild-type allergens and at the same time by substantially retained reactivity with t lymphocytes. These hypoallergenic allergen variants can be employed for the specific immunotherapy (hyposensitisation) of patients having grass pollen allergy or for the preventative immunotherapy of grass pollen allergies..
Merck Patent Gmbh
| Allergy skin test devices with surrounding pain-reduction structures|
An allergy skin testing device is disclosed that includes at least one central post having at least one sharp probe extending longitudinally from an end of the at least one central post, the at least one sharp probe being for administering an allergen to skin. For each central post, at least three dull probes substantially surround the at least one sharp probe, creating a “pain gate fence”, the at least three dull probes being for activating a pain gate effect affecting nerves of the skin while the at leat one sharp probe administers the allergen to the skin.
|Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response|
The invention provides immune regulatory oligonucleotides (iro) as antagonist of tlrs and methods of use thereof. These iros have unique sequences that inhibit tlr-mediated signaling in response to a tlr ligand or tlr agonist.
Idera Pharmaceuticals, Inc.
|A purified extract isolated from pseudolysimachion rotundum var. subintegrum containing abundant amount of active ingredient, the preparation thereof, and the composition comprising the same as an active ingredient for preventing or treating inflammation, allergy and asthma|
A method for preparing purified extract containing more abundant active ingredients such as catalpol derivatives from the extract of pseudolysimachion rotundum var subintegrum than that prepared by the conventional preparation method disclosed in the prior art and the therapeutics or functional health food comprising the purified extract for treating and preventing inflammatory, allergic or asthmatic disease. The purified extract showed more potent anti-inflammatory, anti-allergy and anti-asthma activity than that prepared by the conventional preparation method disclosed in the prior art through various in vivo tests such as inhibition test on the reproduction of eosinophil, the release of immunoglobulin and inflammatory chemokines in plasma and bronchoalveolar fluid as well as the suppression of airway hyperresponsiveness and goblet cell hyperplasia in a ova-sensitized/challenged mouse model..
Korea Research Institute Of Bioscience And Biotechnology
|Molecular identification of allergy causing mites by pcr|
The present invention relates to novel methods for the identification of specific mite species in a sample, such as mass reared sample or an environmental sample. The invention further relates to nucleic acid molecules encoding the structural ribosomal rna elements (rrna) as well as to the non-functional rna situated between such structural ribosomal rnas of specific mite species and its use for designing primers for use in the method..
|Composition for use in treating and preventing inflammation related disorder|
The present invention is related to a use for treating and preventing inflammation related disorder of a composition containing a drug and hyaluronic acid (ha) or ha mixture, whereas the ha or the ha mixture as a delivery vehicle can be a formulation including at least two has having different average molecular weights. The composition has been demonstrated to be capable of reducing the therapeutic dose of a drug on the treatment and prevention of inflammation related disorders is acute inflammatory disease, chronic obstructed pulmonary disease, coeliac disease, conjunctivitis, otitis, allergic rhinitis, gingivitis, aphthous ulcer, bronchitis, gastroesophageal reflux disease (gerd), esophagitis, gastritis, enteritis, peptic ulcer, inflammatory bowel disease (ibd), crohn's disease, irritable bowel syndrome (ibs), intestinal inflammation or allergy, urethritis, cystitis, vaginitis, proctitis, eosinophilic gastroenteritis, or rheumatoid arthritis..
|N-cyanomethylamides as inhibitors of janus kinase|
The present invention relates to compounds of general formula (1) that are inhibitors of janus kinase (jak), a family of tyrosine kinases that are involved in inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6 or interferons. In particular, the compound of the invention inhibits jak1 and/or jak2 and/or jak3 sub families.
|Method for prognosis of the efficacy of oral immunotherapy for the treatment of allergy to proteins in cow's milk|
The present invention relates to a method for prognosis of the efficacy of oral immunotherapy for the treatment of allergy to proteins in cow's milk providing a solution to the problems stated in the state of the art since it provides a method which allows making a prognosis of the number of reactions that will be produced during oral immunotherapy (oit) against proteins in cow's milk and/or an estimate of the treatment time required to achieve tolerance or desensitization during oit against proteins in cow's milk and/or the need for pre-medication during oit in a human subject.. .
Fundación Para La Investigación Biomédica Del Hospital Clinico San Carlos
|Regulatory t cell mediator proteins and uses thereof|
In particular methods of using these proteins and compounds, preferably antibodies, which bind or modulate (agonize or antagonize) the activity of these proteins, as immune modulators and for the treatment of cancer, autoimmune disease, allergy, infection and inflammatory conditions, e.g. Multiple sclerosis is disclosed.
|Anti-allergy benzocycloheptathiophene derivatives|
Or a pharmaceutically acceptable salt thereof, solvate, or prodrug thereof, and a pharmaceutically acceptable carrier, vehicle or excipient.. .
Long-term effective patch structure
A long-term effective patch structure includes a binding layer, an absorbing layer and a water-proof layer sequentially stacked together. The binding layer has a function of attaching and fixing, and is configured to be attached and fixed on a skin.
Sigknow Biomedical Corporation Ltd.
Identification of vsig8 as the putative vista receptor (v-r) and use thereof to produce vista/vsig8 agonists and antagonists
The receptor for vista is identified (vsig8) as well as the use of this receptor in the identification or synthesis of agonist or antagonist compounds, preferably antibodies, polypeptides and fusion proteins which agonize or antagonize the effects of vsig8 and/or vista and/or the vsig8/vista binding interaction. These antagonists may be used to suppress vista's suppressive effects on t cell immunity, and more particularly used in the treatment of cancer, or infectious disease.
Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor
Benzoimidazol-2-yl pyrimidines, purification methods for the same, and pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by h4 receptor activity, including allergy, asthma, autoimmune diseases, and pruritus.. .
Janssen Pharmaceutica Nv
Devices, systems and methods of assessing the foundations for the healthy development of an infant or a young child
Devices, systems and methods assess one or more of the risk of an allergy, immediate and/or later in life, for the infant or young child; the risk of an underdeveloped immune system, immediate and/or later in life, for the infant or young child, and/or the immediate risk of a not well-functioning digestive system for the infant or young child, preferably all of these. Optionally, the risk of obesity, immediate and/or later in life, can be additionally assessed.
Pharmaceutical product comprising mite allergen extract(s) and a the manufacture thereof
The invention relates to a pharmaceutical product comprising an allergen extract or an allergoid thereof for the treatment and/or prevention of allergy and allergic asthma caused by house dust mites, which extract comprises at least one extract of mite bodies selected from the following groups a)-b): a) an extract of der p mite bodies, and b) an extract of der f mite bodies, and at least one extract of mite cultures selected from the following groups c)-g): c) an extract of der p faecal particles, d) an extract of der f faecal particles, e) an extract of der f whole mite culture, f) an extract of an der p whole mite culture, and g) a combination of extracts c) to f).. .
Preparation of bee venom with allergenic components removed
Disclosed is a method for manufacturing a separated and purified bee venom (separated pbv) not possessing allergy-triggering effects by reducing or eliminating allergy-inducing components contained in a bee venom via ultrafiltration, thereby producing a pvb with desirable pharmacological effects while fundamentally blocking allergies that may be induced by the same. The manufacturing method of the present invention includes a first step of preparing a purified bee venom powder; a second step of preparing a bee venom liquid by mixing the purified bee venom powder with distilled water; a third step of removing allergic ingredients contained in the bee venom liquid via ultrafiltration through a membrane having a cut-off size of 10 kda; and a fourth step of obtaining a separated pbv with the allergenic components removed; wherein the distilled water to be mixed with the purified bee venom powder in the second step is used in the range of from 1000 ml to 1500 ml per 1 g of the purified bee venom powder, the allergenic components removed through the ultrafiltration membrane in the third step are phospholipase a2 and hyaluronidase, and the separated pbv obtained in the fourth step contains 4 wt % or higher of apamin, and 50 wt % or higher of melittin..
Chung Jin Biotech Co., Ltd Hanyang Univ Ansan Campus, Sa-dong
Treatment of food intolerance and food allergy with iga
A process is provided for inhibiting symptoms of food allergy or food intolerance in a subject that includes the oral adminstration to the subject suffering from food allergy or food intolerance an igm. When administered in a therapeutic quantity based on the subject characteristics and the type of igm, symptoms of food allergy or food intolerance in that subject are inhibited.
Effector-deficient anti-cd32a antibodies
Effector-deficient anti-cd32a monoclonal antibodies are encompassed, as are method and uses for treating cd32a-mediated diseases and disorders, including, thrombocytopenia, allergy, hemostatic disorders, immune, inflammatory, and autoimmune disorders.. .
Adventist Health System/sunbelt Inc.
An integrated padded mesh material may be used in pillows or pillowcases for improved air flow around a user of the pillow or pillowcase during rest. When used in a pillow, the material may substantially cover the side of the pillow that a user's head rests upon.
Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
The invention provides novel immune regulatory oligonucleotides (iro) as antagonist of tlrs and methods of use thereof. These iros have unique sequences that inhibit or suppress tlr-mediated signaling in response to a tlr ligand or tlr agonist.
Idera Pharmaceuticals, Inc.
T cell epitopes derived from alt a 1 or alt a 5 for the treatment of alternaria alternata allergy
The application discloses peptides capable of preventing or treating fungal disease, including fungal allergy disease.. .
Thin planar biological sensor
A thin planar biological sensor is provided, comprising at least one flexible electrode used for contacting a subject's skin and measuring biological signal. The flexible electrode is made of silicon-silver-based material, in which a ratio of silicon to silver-compound is about 7:3.
National Chiao Tung University
Methods and devices for treating primary headache
Non-invasive electrical nerve stimulation devices and magnetic stimulation devices are disclosed, along with methods of treating medical disorders using energy that is delivered noninvasively by such devices. The disorders comprise migraine and other primary headaches such as cluster headaches, including sinus symptoms that resemble an immune-mediated response (“sinus” headaches), irrespective of whether those symptoms arise from an allergy that is co-morbid with the headache.
Vaccine peptide combinations against cat allergy
The present invention relates to compositions comprising peptides for preventing or treating allergy to cats, and in particular to optimal combinations of peptides. .
Recombinantly produced allergens
Methods for producing an allergen composition, methods for in vitro diagnosis of type i allergy, and diagnostic kits for performing diagnosis employ bos d 23k allergen of seq id no: 4, or the mature protein thereof, or a variant or fragment of the bos d 23k allergen or the mature protein sharing epitopes for antibodies with the bos d 23k allergen or the mature protein. Methods for treatment of a type i allergy to a mammal and pharmaceutical compositions employ a bos d 23k allergen of seq id no: 4, or the mature protein thereof, or a variant or fragment of the bos d 23k allergen or the mature protein sharing epitopes for antibodies with the bos d 23k allergen or the mature protein, wherein the bos d 23k allergen, the mature protein, the variant or the fragment is modified to abrogate or attenuate its ige binding response..
Beverage compositions and other formulations for treating allergies and methods for making the same
A composition for preventing and/or alleviating an allergy related condition and methods of making such compositions are disclosed herein. A composition in accordance with a particular embodiment can include honey having pollen derived from a known plant species and/or from a known geographic location.
Breathable mattress pad and sleeping accessories
Sleeping accessories such as mattress pads, mattress topper covers, and sheet savers are disclosed herein comprising integrated padded mesh material. Integrated padded mesh material, when used in the sleeping accessories, results in improved air flow for the user, which can reduce complications during sleep such as sudden infant death syndrome.
Anti-il-25 antibodies and uses thereof
The present invention provides antibodies that bind to human interleukin-25 (il-25) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human il-25 with high affinity.
Regeneron Pharmaceuticals, Inc.
Horse allergen and methods
A method for performing in vitro diagnosis of type 1 allergy, comprises contacting an immunoglobulin-containing body fluid sample from a patient suspected of having type 1 allergy with an immobilized horse allergen immobilized on a solid support, and detecting the presence, in the sample, of ige antibodies specifically binding to the horse allergen, wherein the presence of such ige antibodies specifically binding to the horse allergen is indicative of type 1 allergy. A method for treatment of type 1 allergy comprises administering to an individual susceptible to such treatment, the horse allergen, or a form of the horse allergen that is modified to abrogate or attenuate its ige binding response.
Rapid allergy testing method
The present invention provides a method for testing an allergy capable of rapidly and highly accurately testing an allergic reaction. The method can determine whether or not a patient has an allergy or whether or not an agent that may be allergenic to a patient has an allergenicity (an allergic reactivity) in the patient.
Refined product obtained from rice hull and preparation process and use thereof
Disclosed herein is a refined product obtained from a rice hull, which consists essentially of a type ii arabinogalactan having a number average molecular weight in the range of 56 to 103 kda. Also disclosed are a process for producing the refined product and use of the refined product for enhancing the biological activity of innate immune cells, as well as for treating allergy and cancer..
China Medical University
Rnai-mediated inhibition of histamine receptor h1-related conditions
Rna interference is provided for inhibition of histamine receptor h1 mrna expression, in particular, for treating patients having an hrh1-related condition or at risk of developing an hrh1-related condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, or allergy.. .
Arrowhead Research Corporation
Novel prostate kallikrein allergen
Methods for treatment of a type i allergy in a mammal comprise administering to an individual in need of such treatment a polypeptide of seq id no: 1 or the mature protein, amino acids 25-260, of the polypeptide of seq id no: 1, or a fragment of the polypeptide or the mature protein, which fragment shares epitopes for antibodies with the polypeptide or the mature protein, respectively, or a hypoallergenic form thereof that is modified to abrogate or attenuate its ige binding response. Diagnostic kits comprise the polypeptide of seq id no: 1 or the mature protein, amino acids 25-260, of the polypeptide of seq id no: 1, immobilized on a solid support..
Urine detection inductor suitable for large-scale production
A detector for wet diaper is suitable for large-scale production. The detector comprises a nonwoven fabric (1) and at least two electrodes (2, 3) which are carbon powder coated on the nonwoven fabric (1).
Tolerogenic synthetic nanocarriers for allergy therapy
Disclosed are synthetic nanocarrier compositions, and related methods, comprising immunosuppressants and mhc class ii-restricted epitopes of an allergen that provide tolerogenic immune responses specific to the allergen.. .
Selecta Biosciences, Inc.
A prefilled medication device, making and using the same
The invention generally relates to prefilled disposable medication devices, method of making, and using to store, contain and deliver at least a diluent for allergenic extract and more particularly to a prefilled cartridge containing a diluent for allergenic extract for use with an injection pen for allergy treatments.. .
Phd Preventive Health Care And Diagnostics, Inc.
Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.. .
Topical ocular preparation of botulinum toxin for use in ocular surface disease
A composition of botulinum toxin is claimed which can penetrate into the ocular surface inclusive of a penetration through a conjunctiva, cornea, and other structures. This composition allows for a maximal penetration of a topical preparation of botulinum toxin which serves to reduce the need for frequent allergy drops for the treatment of ocular surface disease and other conditions causing ocular surface inflammation or deep ocular inflammation.
Botulinum Toxin Research Associates, Inc.
Sprayable oxygenated saline composition and treating nasal congestion, allergy, dryness, eye irritation, throat irritation, wounds, and skin as applied to human tissues
An oxygenated saline composition is provided comprising stabilized oxygen, sodium chloride (aqueous saline solution), and optionally one or more homeopathic components. The stabilized oxygen can include quad-atomic oxygen.
Oxy Bump Corporation
Novel high throughput assay for finding new jak3 interacting compounds, biomolecules, and inhibitors.
Janus kinase 3 is a non-receptor tyrosine kinase that mediates signals initiated by cytokines through interactions with the receptors of cytokines. Abnormal activation of jak3 was associated with human hematologic and epithelial malignancies.
Method of genetically altering and producing allergy free cats
A transgenic cat with a phenotype characterized by the substantial absence of the major cat allergen, fel d i. The phenotype is conferred in the transgenic cat by disrupting the coding sequence of the target gene with a specialized construct.
System and multiple allergen testing
The testing apparatus includes a capsule 108 tray and a hand held allergen applicator 104 that facilitates convenient storage and easy application of such allergens simultaneously. The hand held applicator 104 includes a plurality of prongs to administer the respective plurality allergen under the skin of the patient.
Peptide carrier fusion proteins as allergy vaccines
The present invention relates to a polypeptide comprising at least three peptide fragments consisting of 10 to 50 consecutive amino acid residues of at least one wild-type allergen fused to the n- and c-terminus of a surface polypeptide of a virus of the hepadnaviridae family or at least one fragment of said surface polypeptide.. .
Design of oligonucleotide analogs as therapeutic agents
It is believed that the compounds and compositions as described herein have therapeutic utility against a variety of diseases, including viral diseases, autoimmune diseases (such as, allergy, asthma, and inflammatory disorders) and cancer.. .
Igy composition for use in celiac disease
The present invention relates to an igy composition characterized in that said igy composition contains igy antibodies, fragments, and/or fab fragments thereof that specifically bind to a peptide with the amino acid sequence of seq id no: 1 and to the use of this igy composition in the therapy of celiac disease, rheumatism, and/or wheat allergy.. .
Charite - Universitatsmedizin Berlin
Novel immunotherapeutic molecules and uses thereof
The present invention relates generally to molecules such as peptides, polypeptides and proteins which interact immunologically with t lymphocytes in subjects having peanut allergy, or allergy to other tree nuts, and genetic sequences encoding same. These molecules are preferably immunointeractive with t cells in subjects having an allergy to the ara h 1 allergen.
Animal food composition and process for production
An animal food composition comprising a protein source and corn starch, wherein native high-amylose corn starch comprises at least 50% of the corn starch. The composition can be used to treat or prevent a food allergy in an animal.
Hill's Pet Nutrition, Inc.
Process for producing an allergen extract
The present invention discloses processes for producing native, depigmented and polymerised allergen extracts. The invention further discloses extracts produced via the processes, and pharmaceutical and vaccine compositions comprising the extracts, for diagnosis and treatment of allergy..
Laboratorios Leti, S.l.
Methods of treating or preventing respiratory conditions
The present disclosure provides methods of treating or preventing respiratory condition and/or for treating an ige-mediated allergy and/or for reducing an allergic response to an allergen and/or for inducing anergy to an allergen in a subject and/or improving lung function in a subject suffering from an allergy comprising administering to a subject a population of cells enriched for stro-1+ cells and/or progeny thereof and/or soluble factors derived therefrom.. .
New fusion proteins for the treatment of allergic diseases
The present invention relates to a fusion protein comprising a first peptide and a second peptide linked together with a linker, wherein the first peptide is an allergen and the second peptide is a targeting unit and the targeting unit is a fgl-2 c-terminal peptide according to seq id no 1. Provided herein are also uses of said fusion protein as a vaccine for treating allergy, such as shrimp, peanut or mite allergy, as well as a vaccine composition and methods for producing such fusion proteins..
Bifidobacterium for dust mite allergy
A composition comprising bifidobacterium breve for use in improving lung function in human subjects suffering from dust mite allergy.. .
Allergy treatment using acid treated aqueous whey protein extract
The invention relates to manufacture of whey protein extracts, to infant formula and to reducing or preventing food allergy. The whey protein extract is produced from a whey protein-containing composition by contacting a whey protein-containing composition with an aqueous solution to form a sample including a soluble protein-containing component and an insoluble component; recovering the soluble protein-containing component from the sample; and acidifying the soluble protein-containing component, thereby producing the whey protein extract.
Women's And Children's Health Research Institute
System and automatic reading of an allergy
A system and method for automatic reading skin for an allergy to a substance, includes a consumer electronics device that acquires images of skin; a consumable member having a surface divided into elementary areas, each elementary area with a different possible allergenic substance; and a palette that, when applied against each elementary area brings the depositing part into contact with the skin thereby depositing the corresponding possible allergenic substance on or under the skin, where an image processing operation of the image of the skin taken by the consumer electronics device localizes the location that each depositing part has deposited the possible allergenic substance during the application and provides information in relation with a sensitivity of the skin, as indicated by a visible reaction, to the possible allergenic substance at each localized location.. .
Allergy skin test applicator, and related testing tray, testing kit and testing method
An allergy testing kit contains a plurality of allergy testing applicators, an allergy testing tray and a plurality of allergen bottles each containing an allergen. Each of the applicators contains an elongated handle, a plurality of arms extending from the elongated handle and disposed in an asymmetrical configuration, and a plurality of legs with tines extending from each of the arms.
Wheat proteomic microarray for biomarker discovery
This invention pertains to the preparation of arrays containing the proteome of wheat, including gluten and non-gluten proteins. Antibodies to wheat gluten have been shown to be elevated, not only in celiac disease and wheat allergy, but also in neuropsychiatric disorders, such as schizophrenia, bipolar disorder, and autism.
The Trustees Of Columbia University In The City Of New York
M cells and artificial skin sheet
[problem] to provide m cells having excellent strength and anti-allergy activity and an artificial skin sheet formed from the m cells. [solution] gp2 contained in the m cells is transferred to the intracellular tight junction and galectin 9 is expressed in the m cells.
Plastic blood lancet
The present invention provides a surgically invasive pointed article for skin penetration and capillary whole blood extraction whose penetration ability can be disabled after use by deforming the tips. The present invention is made by injection moulding a plastic needle 35 having an anchoring means 45 using a first material, followed by another injection moulding process to over-mould a first body segment 20 and second body segment 30 using a second material to encase the plastic needle 35 thereby anchoring the plastic needle 35 to prevent further movement of the plastic needle 35.
Compositions for immunotherapy
The present invention relates to compositions which can be used in immunotherapy and especially to compositions which can be used in immunotherapy for mammals suffering from a peanut allergy. The present invention further relates to the use of the present compositions for the treatment of a mammal suffering from an allergy by immunotherapy and the use of the present compositions in a prophylactic treatment for desentizing the immune system of a mammal for an allergen.
Hal Allergy Holding B.v.
Nutritional compositions containing ceramide and uses thereof
The present disclosure relates to nutritional compositions that include at least one ceramide. The nutritional compositions may further include galactose, sialic acid, or cholesterol.
Mead Johnson Nutrition Company
Benzimidazole derivatives as pi3 kinase inhibitors
This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3′ oh kinase family (hereinafter pi3 kinases), suitably, pi3kα, pi3kδ, pi3kβ, and/or pi3kγ. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries.
Substituted fused tricyclic compounds, compositions, and medicinal applications thereof
The compounds of the present invention are useful in the treatment, prevention or suppression of diseases and disorders mediated by jak activity. Such conditions include, but not limited to, arthritis, alzheimer's disease, autoimmune thyroid disorders, cancer, diabetes, leukemia, t-cell prolymphocytic leukemia, lymphoma, myleoproliferation disorders, lupus, multiple myeloma, multiple sclerosis, osteoarthritis, sepsis, psoriatic arthritis, prostate cancer, t-cell autoimmune disease, inflammatory diseases, chronic and acute allograft transplant rejection, bone marrow transplant, stroke, asthma, chronic obstructive pulmonary disease, allergy, bronchitis, viral diseases, or type i diabetes, complications from diabetes, rheumatoid arthritis, asthma, crohn's disease, dry eye, uveitis, inflammatory bowel disease, organ transplant rejection, psoriasis and ulcerative colitis.
Novel histamine releaser contained in human sweat
Provided arc a sweat allergy antigen, an antibody capable of binding to the antigen specifically, and others, which are produced utilizing a microorganism-originated protein that exists in sweat allergy patient in a dissolved state or a partial peptide of the protein.. .
Use of anti-cd1 antibodies for the modulation of immune responses
The invention provides methods for the administration of an anti-cd1 antibody for the treatment or prevention of a variety of disorders, such as autoimmune disease, viral infection, bacterial infection, parasitic infection, infection by a eukaryotic pathogen, allergy, asthma, inflammatory condition, graft versus host disease, graft rejection, immunodeficiency disease, spontaneous abortion, pregnancy, and cancer.. .
Beth Israel Deaconess Medical Center, Inc.
Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
Useful in the prophylaxis and/or treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving degradation and/or disruption of cartilage homeostasis, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6 or interferons.. .
Pharmaceutical compositions for the treatment of inflammatory disorders
Useful in the prophylaxis and/or treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving degradation and/or disruption of cartilage homeostasis, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6 or interferons.. .
Probiotics for use in reducing eosinophilia and respiratory allergies
The present invention provides probiotic compositions suitable for reducing the incidence and duration of nasal eosinophilia and other parameters associated with birch pollen allergy. In some embodiments, the present invention provides methods and/or compositions suitable for reducing nasal and/or respiratory allergy symptoms..
Dupont Nutrition Biosciences Aps
Compositions and methods for modulation of rorgammat functions
The present invention relates to expression of rorγt in cells and tissues and the effect of expression of this gene on proliferation of specific immune cells and in promotion of immune cell aggregates and in induction of il17 producing cells. Furthermore, the invention relates to methods and agents that may decrease function of the gene product (the protein) or expression of this gene in individuals experiencing an inflammatory condition, an autoimmune disease or a food allergy, or any other condition whereby it is desirable to inhibit an immune response.
Polypeptides which may be used for preventing or treating allergy to moulds of the cladosporium and/or alternaria genus, have up to 30 amino acids in length and comprise: (i) the amino acid sequence: (a) ggykaavrptmle (seq id no: 35; cla35), (b) ae v yqklk sltkk (seq id no: 31; cla16), (c) vaityasraqgae (seq id no: 32; cla25), (d) ghhfkergt-gslvit (seq id no: 33; cla26), or (e) anytqtktvsirl (seq id no: 34; cla29); or (ii) a t cell epitope-containing variant sequence which is a said amino acid sequence (i) having up to six amino acid modifications, each of which is independently a deletion, substitution or insertion.. .
Allergy testing device and testing for allergies
An allergy testing system comprises a skin test device having a grip portion for holding the device. One or more legs extend from the grip, and each leg is oriented to interact with a well containing a potential allergen.
Lincoln Diagnostics, Inc.
Monoclonal lge antibody that binds to sweat allergy antigen protein
Provided include a human ige antibody that binds to a sweat allergy antigen protein and a human high-affinity ige receptor but does not induce degranulation in a reaction with the sweat allergy antigen protein, and a composition for treatment or diagnosis of sweat allergy comprising the same.. .
Novel allergen from ragweed pollen and uses thereof
The present invention notably concerns a novel major allergen from ragweed pollen, named amb a x, as well as isoallergens and isoforms thereof. Fragments of the aforementioned polypeptides and homologous polypeptides, in particular homologous polypeptides in related plant species, also make part of the invention.
Compositions and methods relating to the treatment of diseases
A method is provided for the treatment and/or prophylaxis of a condition where an enhancement of a th1-mediated immune response and suppression of a th2/th17-mediated immune response are desired. The method comprises the step of administering to a subject in need thereof a therapeutically effective amount of at least one interferon alpha subtype selected from ifn-α10, ifn-α14, and a hybrid thereof.
Inhibition of gliadin peptides
Novel compounds and methods for the inhibition of biological barrier permeability and for the inhibition of peptide translocation across biological barriers are identified. Assays for determining modulators of biological barrier permeability and for peptide translocation across biological barriers are provided.
Alba Therapeutics Corporation
Peptides for vaccine against birch allergy
The present invention relates to compositions comprising peptides for preventing or treating allergy to birch, and in particular to optimal combinations of peptides for preventing or treating said allergy.. .
Hypo-allergenic cross-linked proteins for use in the prevention of an allergy against milk-proteins and for use in the induction of oral tolerance
The present invention provides a hypo-allergenic cross-linked protein for use in the prevention of an allergy against milk proteins, or for use in the induction of oral tolerance for milk proteins, said cross-linked protein being selected from cross-linked casein, cross-linked caseinate and combinations thereof. The invention further provides a nutritional composition for use in the prevention of an allergy against milk proteins or for use in the induction of oral tolerance against milk proteins..
Friesland Brands B.v.
Treatment of lge-mediated disease
The methods and compositions described herein are based, in part, on the discovery of a polypeptide of soluble cd23 (scd23) that binds and sequesters ige. Thus, the scd23 peptides, polypeptides and derivatives described herein are useful for treating conditions or disorders involving increased ige levels such as e.g., allergy, anaphylaxis, inflammation, lymphoma, and certain cancers..
Trustees Of Boston University
Alpha-enolase specific antibodies and use in immune diseases
A method for treating an inflammatory disease or an immune disorder includes administering to a subject in need of such treatment an antagonist against eno1. The antagonist binds eno1 and inhibits eno1 plasminogen receptor activity.
Development Center For Biotechnology
Nanoparticles for treatment of allergy
The present invention encompasses the surprising finding that nanoparticle compositions can have beneficial effects on allergy even when prepared without a known specific allergy therapeutic. The present invention provides such nanoparticle compositions.
Allertein Therapeutics, Llc
Allergy topics: Autoimmune, Prophylactic, Ophthalmic, Autoimmune Disorder, Immune Disorder, Dermatitis, Staurosporin, Aspergillosis, Angioedema, Allergic Rhinitis, Food Allergy, Therapeutical, Bronchopulmonary, Staurosporine, Sudden Infant Death
Follow us on Twitter
This listing is a sample listing of patent applications related to Allergy for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Allergy with additional patents listed. Browse our RSS directory or Search for other possible listings.